Citigroup Inc. Reiterates “$100.00” Price Target for AveXis Inc (AVXS)

Citigroup Inc. set a $100.00 target price on AveXis Inc (NASDAQ:AVXS) in a report issued on Thursday morning. The brokerage currently has a buy rating on the stock.

AVXS has been the topic of several other reports. BMO Capital Markets restated an outperform rating and issued a $95.00 price objective (up from $85.00) on shares of AveXis in a report on Friday, March 17th. Jefferies Group LLC upped their price objective on shares of AveXis from $79.00 to $92.00 and gave the stock a buy rating in a report on Friday, March 17th. Goldman Sachs Group, Inc. (The) upped their price objective on shares of AveXis from $91.00 to $108.00 and gave the stock a buy rating in a report on Friday, March 17th. Finally, Chardan Capital restated a buy rating and issued a $100.00 price objective on shares of AveXis in a report on Friday, March 17th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. AveXis presently has a consensus rating of Buy and an average price target of $87.86.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Shares of AveXis (NASDAQ:AVXS) opened at 72.03 on Thursday. The stock’s 50 day moving average is $74.27 and its 200 day moving average is $65.34. The company’s market cap is $2.00 billion. AveXis has a 1-year low of $31.55 and a 1-year high of $85.98.

AveXis (NASDAQ:AVXS) last posted its quarterly earnings results on Thursday, May 11th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.94) by $0.13. During the same quarter last year, the firm earned ($1.24) EPS. On average, analysts predict that AveXis will post ($4.56) earnings per share for the current year.

WARNING: “Citigroup Inc. Reiterates “$100.00” Price Target for AveXis Inc (AVXS)” was originally published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/2654713/citigroup-inc-reiterates-100-00-price-target-for-avexis-inc-avxs.html.

In other news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $81.39, for a total value of $144,874.20. Following the transaction, the vice president now directly owns 1,780 shares in the company, valued at approximately $144,874.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders sold 5,341 shares of company stock worth $406,682.

Several institutional investors have recently modified their holdings of AVXS. Quantbot Technologies LP bought a new position in shares of AveXis during the first quarter valued at approximately $117,000. Quantitative Systematic Strategies LLC bought a new position in shares of AveXis during the first quarter valued at approximately $201,000. Virginia Retirement Systems ET AL bought a new position in shares of AveXis during the first quarter valued at approximately $205,000. Opus Point Partners Management LLC bought a new position in shares of AveXis during the fourth quarter valued at approximately $239,000. Finally, Nationwide Fund Advisors raised its position in shares of AveXis by 9.0% in the first quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock valued at $262,000 after buying an additional 284 shares in the last quarter. Hedge funds and other institutional investors own 90.47% of the company’s stock.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:AVXS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.